Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Weight loss isn't just a matter of willpower its a matter of biology
Participants taking Wegovy more frequently reported: nausea diarrhea constipation vomiting The trial also revealed compelling secondary benefits, with improvements in key comorbidities, including: type 2 diabetes obesity cardiovascular risk markers Most notably, people taking Wegovy lost significantly more weight than those receiving a placebo an average of 10% of body weight compared to just 2%
In this population, 53% of individuals had commercial health insurance, 18% had Medicare, 11% had Medicaid, 1% had Dual (Medicare/Medicaid) coverage, and 17% had other coverage (e.g., Tricare, Veterans Affairs, or other State or local programs)
Endocrinology 153, 22082222
Couzin-Frankel J, Vogel G
A warning can found in the label as well (GLP-1 agonists may not be used in people with history or family history of medullary thyroid cancer or certain endocrine conditions, like Multiple Endocrine Neoplasias)
US$ 26.11
US$ 22.36
US$ 25.36
US$ 22.42
US$ 22.92
US$ 26.20
US$ 22.09
US$ 20.92
US$ 21.59
